alphafold

Researchers used AlphaFold AI to identify and redesign parts of gene-editing proteins (Cas9) responsible for off-target effects, significantly improving safety by reducing unintended edits.

Vertu's Alphafold luxury foldable phone, starting at $6,880, features an AI agent called Hermes Agent for executive tasks like document analysis, workflow automation, and travel planning. While the hardware is premium, the AI performance is tested against its value proposition.

Google DeepMind and Isomorphic Labs outline their joint approach to bioresilience, focusing on preventing misuse of AI models and using AI to improve prevention, detection, and response to infectious disease outbreaks through partnerships and tools like AlphaFold, Gemini, and SynthID.

In three days, Noam Shazeer (co-author of the Transformer paper) left Google for OpenAI, and Nobel laureate John Jumper (AlphaFold lead) left Google DeepMind for Anthropic, marking significant talent shifts in AI.

The article profiles chemist Tim Cernak, who applies AI-driven drug design (like AlphaFold) to develop precision treatments for wildlife, coining the field 'conservation chemistry' to address mass extinction with cutting-edge tools.

DeepMind founder Demis Hassabis delivers a 60-minute speech at the University of Cambridge, covering the future development of AI from large models, AlphaFold to scientific discovery and AGI. Video has been added with Chinese subtitles.

ProtStructQA introduces an executable benchmark for protein structural question answering that compiles natural language queries into a typed DSL program to evaluate LLMs on precise 3D measurements, revealing a capability-dependent denotation threshold where chain-of-thought becomes strongly beneficial above a certain model scale.

Google I/O keynote highlighted a shift in AI-driven science, contrasting specialized tools like WeatherNext with the rise of agentic AI systems that can conduct research autonomously, signaling a realignment in resources and enthusiasm.

A critical analysis of Google DeepMind CEO Demis Hassabis's claim at Google I/O that AI could 'solve all diseases,' contextualizing the potential of tools like AlphaFold and AlphaGenome while highlighting the gap between scientific promise and public perception.

Demis Hassabis claims AI can cure all diseases within 10 years, backed by a $2.1B funding round for Isomorphic Labs to accelerate AI-driven drug discovery and personalized medicine.

The article reviews DeepMind's decision-making process behind open-sourcing AlphaFold in 2021, praising Demis Hassabis's leadership style for taking risks and freely making basic research available. It also notes that although this initiative did not generate direct profits, it successfully led to the creation of Isomorphic Labs, valued at $2 billion.

This article reflects on the five-year impact of AlphaFold since its 2020 breakthrough, highlighting its role as a global scientific tool used by millions of researchers and its recognition with the 2024 Nobel Prize in Chemistry.

Demis Hassabis spoke at the Google for KOREA event, reflecting on AlphaGo's 10th anniversary and AlphaFold winning the Nobel Prize, while offering advice for Korea's AI future, leaders, and next-generation education.

AI tools such as AlphaFold help Ugandan researchers conduct local cancer genetic research, narrowing breast cancer vaccine candidate targets from 15,000 to 15. This significantly lowers the research threshold and demonstrates the potential for democratizing science.